

Informazione Regolamentata n. 0957-6-2020

Data/Ora Ricezione 02 Marzo 2020 07:58:36

MTA

Societa' : DiaSorin

Identificativo : 128147

Informazione

Regolamentata

Nome utilizzatore : DIASORINN01 - Fava

Tipologia : REGEM

Data/Ora Ricezione : 02 Marzo 2020 07:58:36

Data/Ora Inizio : 02 Marzo 2020 07:58:37

Diffusione presunta


Oggetto : DiaSorin signs an exclusive licensing

agreement for molecular diagnostic POC

technology

Testo del comunicato

Vedi allegato.



DIASORIN AND TTP SIGN EXCLUSIVE LICENSING AGREEMENT FOR MOLECULAR DIAGNOSTIC POINT-OF-CARE TECHNOLOGY

March 2, 2020 - Saluggia, Italy and Cambridge, UK - DiaSorin (FTSE MIB: DIA) and TTP plc, a leading independent technology and product development company, today announced that they have signed an exclusive licensing and technology transfer agreement under which DiaSorin will gain access to TTP's PuckdxTM, a flexible and low-cost platform for the automation of sample-to-answer diagnostic assays.

The agreement follows DiaSorin's strategy to identify a point-of-care (POC) platform that can be combined with DiaSorin's extensive range of molecular tests, providing results to clients in less than 15 minutes, through a simple and cost-effective technology solution.

TTP's Puckdx platform is based on a unique disposable robotic pipette system with a fast PCR module, combined with easy-to-use cartridge containing all the necessary reagents.

DiaSorin estimates that the first test on this platform will be made commercially available in the US by 2023.

POC testing is performed in a healthcare setting closer to patients, such as emergency departments, outreach clinics, physician offices, retail clinics, pharmacies, assisted living and home.

Around 15–25% of the current testing volume in centralized molecular labs is expected to be decentralized driven by an increasing prevalence of infectious diseases and a need to reduce the time from diagnosis to a more precise treatment. There is also an increased need for greater efficiencies, which is driven by seasonal spike alleviation in testing volumes and the need to reduce labor costs.

Today in the US, 12,000 pharmacies and 2,000 small clinics already offer some diagnostic services and this segment of the market is growing by 18% per year in volume. Decentralization of testing makes diagnostic services more affordable and convenient for patients. Moreover, availability of certain tests in controlled but decentralized locations is considered by some experts the only effective way to respond to emergencies created by infectious agents like the current Coronavirus outbreak.

Carlo Rosa, CEO of DiaSorin Group, commented: "This agreement represents a great opportunity for DiaSorin Molecular to expand from bench top systems, placed in centralized hospitals and reference labs, into sites closer to the point of patient care, following the trend identified in all major markets. As announced at our last Capital Market Day, this agreement follows our strategy to explore the decentralization process in the labs setting, with the combination of TTP's very fast and profitable instrument and our extensive molecular diagnostics menu in upper respiratory diseases."



The Diagnostic Specialist



About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the "Diagnostic Specialist."

Further information can be found at www.diasoringroup.com

About TTP plc

TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. Working across a wide spectrum of industries including health, telecoms, industrials and consumer, TTP creates breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all. Further information can be found at www.ttp.com

For additional information, please contact:

For DiaSorin Riccardo Fava

Corporate Vice President Communication & Investor Relations Tel. +39.0161.487988 riccardo.fava@diasorin.it

For TTP

Sam Zacherino
Head of Marketing and Communications
Tel: +44763262626
press@ttp.com

Emanuela Salvini

Investor Relator Tel. +39.0161.487567 emanuela.salvini@diasorin.it

Fine Comunicato n.0957-6	Numero di Pagine: 4